Advertisement

PharmacoEconomics German Research Articles

, Volume 8, Issue 2, pp 109–118 | Cite as

Die Nutzung von Geninformationen für eine personalisierte Pharmakotherapie: Stand, Zukunftspotenziale und wirtschaftliche Implikationen

  • Stefan Sohn
  • Philipp Dornstauder
  • Oliver Schöffski
Übersichtsartikel

The use of genetic information for personalised pharmacotherapy: current status, future prospectives, economic implications

Abstract

Objective

In pharmacotherapy „personalised medicine“ based on genetic information has developed in recent years. To assess its implications a review was conducted on its current status, its prospective potential and its impact on health expenditures.

Study design

A systematic literature review was conducted to assess personalised/individualised medicine using genetic information in pharmacotherapy.

Results

Personalised medicine has the potential to optimise medical treatments. The first active agents with a mandatory DNA test are already available. It is predicted that the focus of pharmacogenetics in the future will concentrate on cancer, palliative medicine and psychiatry. Although the present influence on practice is assessed as low, it is assumed that the DNA test will be mandatory in the mid to long-term for a large proportion of cancer therapies. Genetic information may influence the efficacy of approximately 50% of pharmaceuticals in the market. Due to the variety of economic consequences with different effects and still weak evidence no definite forecasts can be given about cost trends.

Conclusions

Pharmacogenetics and pharmacogenomics will have a clear impact on pharmacotherapy in the forthcoming years. For a valid estimation of the economic impacts more health economic studies in this context are needed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Fierz W. Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends? Med Sci Monit 2004; 10(5): RA 111–23Google Scholar
  2. 2.
    Abrahams E, Ginsburg GS, Silver M. The Personalized Medicine Coalition: goals and strategies. Am J of Pharmacogenomics 2005; 5(6): 345–55CrossRefGoogle Scholar
  3. 3.
    Karger C, Robertz N, Hüsing B. Personalisierte Medizin im Gesundheitssystem der Zukunft, Mai 2009, Förderkennzeichen 01GP0772. Erhältlich unter URL: http://www.fz-juelich.de/inm/inm-8/pdf/personalisierte_medizin.pdf [Abgerufen 31.03.2010]
  4. 4.
    Kollek R, Feuerstein G, Schmedders M. Pharmakogenetik: Implikationen für Patienten und Gesundheitswesen. Anspruch und Wirklichkeit der „individualisierten Medizin“. Baden-Baden: Nomos Verlagsgesellschaft, 2004Google Scholar
  5. 5.
    Lesko LJ. Personalized Medicine: elusive dream or imminent reality? Clin Pharmacol Ther 2007; 81(6): 807–16PubMedCrossRefGoogle Scholar
  6. 6.
    Hüsing B, Hartig J, Bührlen B, et al. Individualisierte Medizin und Gesundheitssystem, Juni 2008, Arbeitsbericht Nr. 126. Erhältlich unter URL: http://www.bio-pro.de/magazin/umfeld/index.html?artikelid=%2Fartikel%2F03912%2Findex.html&lang=de&download=NHzLpZeg7t, lnp6I0NTU042l2Z6ln1acy4Zn4Z2qZpnO2Yuq2Z6gpJCDfIJ6gmym162epYbg2c_JjKbNoKSn6A— [Abgerufen 31.03.2010]
  7. 7.
    Deloitte Development LLC. Targeted Therapies. Navigating the Business Challenges of Personalized Medicine, 2007. Erhältlich unter URL: http://www.deloitte.com/assets/Dcom-UnitedStates/Local%20Assets/Documents/us_chs_targetedTherapies_012307(1).pdf [Abgerufen 31.03.2010]
  8. 8.
    Lindpaintner K. Pharmacogenetics and Pharmacogenomics. In: Fennell JP, Baker AH. Hypertension: Methods and Protocols 2005; 108(3): 235–60Google Scholar
  9. 9.
    Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250(3): 186–200PubMedCrossRefGoogle Scholar
  10. 10.
    Aspinall MG, Hamermesh RG. Realizing the promise of personalized medicine. Harv Bus Rev 2007; 85(10): 108–17,165PubMedGoogle Scholar
  11. 11.
    Rippe K, Bachmann A, Faisst K, et al. Pharmakogenetik und Pharmakogenomik: Studie des Zentrums für Technologiefolgen-Abschätzung, TA48/2004. Erhältlich unter URL: http://www.ta-swiss.ch/a/biot_phar/2004_48_Pharmakogen_d.pdf [Abgerufen 26.03.2010]
  12. 12.
    Scharplatz M, Puhan M, Steurer J, et al. Pharmakogenetik — Wege zu einer individualisierten Therapie? Praxis 2004; 93(10): 359–65PubMedCrossRefGoogle Scholar
  13. 13.
    Kollek R, Dettloff M, Halbsguth C, et al. Pharmakogenetik: Stand und Perspektiven: Aktualisierte Synopse sieben europäischer Studien im Auftrag des Büros für Technikfolgen-Abschätzung beim Deutschen Bundestag (TAB). Hamburg: Universität Hamburg Forschungsschwerpunkt Biotechn Gesellsch Umwelt, 2005Google Scholar
  14. 14.
    Roots I, Laschinski G, Arjomand-Nahad F, et al. Genotype and Phenotype Relationship in Drug Metabolism. In: Venitz J, Sittner W. Appropriate Dose Selection — How to Optimize Clinical Drug Development: Springer Berlin Heidelberg; 2007: 81–100CrossRefGoogle Scholar
  15. 15.
    Seeringer A, Kirchheiner J. CYP2D6-, CYP2C9- und CYP2C19-basierte Arzneimitteldosisanpassungen — Wann sind sie sinnvoll? Der Internist 2008; 49(7): 877–83PubMedCrossRefGoogle Scholar
  16. 16.
    Roche Deutschland Holding GmbH. Was ist HER2? Erhältlich unter URL: http://www.roche.de/pharma/indikation/onkologie/brustkrebs/diagnostik/her2/was_ist.html [Abgerufen 31.03.2010]
  17. 17.
    Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol 2002; 3(3): 137–44PubMedCrossRefGoogle Scholar
  18. 18.
    Wu AC, Fuhlbrigge AL. economic evaluation of pharmacogenetic tests. Clin Pharmacol Ther 2008; 84(2): 272–4PubMedCrossRefGoogle Scholar
  19. 19.
    Büro für Technikfolgen-Abschätzung beim Deutschen Bundestag. Hennen L, Sauter A. Pharmakogenetik: Sachstandsbericht im Rahmen des Monitoring Gendiagnostik/Gentherapie. TAB-Hintergrundpapier Nr. 013. Berlin, 2005. Erhältlich unter URL: http://www.tab.fzk.de/de/projekt/zusammenfassung/hp13.pdf [Abgerufen 31.03.2010]
  20. 20.
    van Delden J, Bolt I, Kalis A, et al. Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. Bioethics 2004; 18(4): 303–21PubMedCrossRefGoogle Scholar
  21. 21.
    Marx-Stölting L. Pharmakogenetik und Pharmakogentests. Biologische, wissenschaftliche und ethische Aspekte des Umgangs mit genetischer Variation. Berlin: LIT Verlag Dr. W. Hopf, 2007Google Scholar
  22. 22.
    Schmidt W, Müller M. Pharmacogenetics (PGx) and Dose Response: Dose Individualization. In: Krishna R. Dose Optimization In Drug Development. New York, London: Informa Healthcare; 2006: 159–94CrossRefGoogle Scholar
  23. 23.
    Omenn GS, Motulsky AG. Integration of Pharmacogenomics into Medical Practice. In: Rothstein MA. Pharmacogenomics: Social, Ethical, and Clinical Dimensions. Hoboken: John Wiley and Sons; 2003: 135–61Google Scholar
  24. 24.
    Cohen N, Frangiosa T. Challenges, Opportunities, and Evolving Landscapes in Pharmacogenomics and Personalized Medicine: An Industry Perspective. In: Cohen N, Editor. Pharmacogenomics and Personalized Medicine. Totowa: Humana Press, 2008: 1–26CrossRefGoogle Scholar
  25. 25.
    Jørgensen JT. From blockbuster medicine to personalized medicine. Personalized Medicine 2008; 5(1): 55–63CrossRefGoogle Scholar
  26. 26.
    Ozdemir V, Williams-Jones B, Glatt SJ, et al. Shifting emphasis from pharmacogenomics to theragnostics. Nature Biotechnol 2006; 24(8): 942–6CrossRefGoogle Scholar
  27. 27.
    Baessler A, Fischer M, Hengstenberg C, et al. Paradigmenwechsel im Gesundheitswesen — Paradigmenwandel in der Medizin. Prospektion, Prävention und Personalisierung. Dtsch med Wochenschr 2006; 131(6): 278–81PubMedCrossRefGoogle Scholar
  28. 28.
    Reeder CE, Dickson WM. Economic Implications of Pharmacogenomics. In: Rothstein MA. Pharmacogenomics: Social, Ethical, and Clinical Dimensions. Hoboken: John Wiley and Sons; 2003: 227–50Google Scholar
  29. 29.
    Melzer D, Raven A, Detmer D, et al. My Very Own Medicine: What Must I Know? Information Policy for Pharmacogenetics, 2003. Erhältlich von URL: http://www.phgfoundation.org/reports/4959/ [Abgerufen 28.10.2010]
  30. 30.
    Costa-Scharplatz M, van Asselt AD, Bachmann LM, et al. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor. Pharmacogenet Genomics 2007; 17(5): 359–68PubMedCrossRefGoogle Scholar
  31. 31.
    Theranostics (NZ) Ltd. DNA tests for Heart medication. Erhältlich unter URL: http://www.theranostics.co.nz/afawcs0143121/CATID=3/page=1/dna_tests_for_heart_medication.html [Abgerufen 10.10.10]
  32. 32.
    Matrix Genomics Inc. Drug Reponse: Genetic differences often determine drug benefits — and adverse events! Erhältlich unter URL: http://www.matrixgenomics.com/drug-response.php [Abgerufen 10.10.10]
  33. 33.
    MyMedLab Inc. CYP450 2C19 (PlavixTM) Gene Test/Genetic Physician Consult. Erhältlich unter URL: https://www.mymedlab.com/products/search?q=plavix [Abgerufen 10.10.10]
  34. 34.
    Eckman MH, Rosand J, Greenberg SM, et al. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009; 150(2): 73–83PubMedGoogle Scholar
  35. 35.
    Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329(7456): 15–9PubMedCrossRefGoogle Scholar
  36. 36.
    Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009; 4(2): e4439PubMedCrossRefGoogle Scholar
  37. 37.
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279(15): 1200–5PubMedCrossRefGoogle Scholar
  38. 38.
    Mjörndal T, Boman MD, Hägg S, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 2002; 11(1): 65–72PubMedCrossRefGoogle Scholar
  39. 39.
    Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24(2): 46–54PubMedCrossRefGoogle Scholar
  40. 40.
    Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharmac Assoc 2001; 41(2): 192–9Google Scholar
  41. 41.
    Evans RS, Classen DC, Stevens LE, et al. Using a hospital information system to assess the effects of adverse drug events. Proc Annu Symp Appl Med Care 1993: 161–5Google Scholar
  42. 42.
    Manasco PK, Arledge TE. Drug Development Strategies. In: Rothstein MA. Pharmacogenomics: Social, Ethical, and Clinical dimensions. Hoboken: John Wiley and Sons; 2003: 83–97Google Scholar
  43. 43.
    Kirchheiner J, Fuhr U, Brockmöller J. Pharmacogenetics-based therapeutic recommendations — ready for clinical practice? Nat Rev Drug Discov 2005; 4(8): 639–47PubMedCrossRefGoogle Scholar
  44. 44.
    Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007; 1770(3): 489–94PubMedCrossRefGoogle Scholar
  45. 45.
    Oggier W. Mögliche Auswirkungen von Pharmacogenomics auf Heilungskosten und Versicherungen. Schweizerische Ärztezeitung 2004; 1978–83Google Scholar
  46. 46.
    Paci D, Ibarreta D. Economic and Cost-Effectiveness Considerations for Pharmacogenetics Tests: An Integral Part of Translational Research and Innovation Uptake in Personalized Medicine. Curr Pharmacogenom Personal Med (Formerly Current Pharmacog) 2009; 7(4): 284–96CrossRefGoogle Scholar
  47. 47.
    Hagaman JT, Kinder BW, Eckman MH. Thiopurine S-methyltranferase testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 2010; 188(2): 125–32PubMedCrossRefGoogle Scholar
  48. 48.
    Heitjan DF, Asch DA, Ray R, et al. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J 2008; 8(6): 391–9PubMedCrossRefGoogle Scholar
  49. 49.
    Garber AM, Tunis SR. Does comparative-effectiveness research threaten personalized medicine? N Engl J Med. 2009; 360(19): 1925–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Stefan Sohn
    • 1
  • Philipp Dornstauder
    • 1
  • Oliver Schöffski
    • 1
  1. 1.Lehrstuhl für GesundheitsmanagementFriedrich-Alexander-Universität Erlangen-NürnbergNürnbergDeutschland

Personalised recommendations